MicroDental Laboratories today announced the launch of ProSomnus Sleep Technologies, featuring MicrO2 Sleep Apnea Device. This move enables ProSomnus to better align and focus resources with the needs of dentists who are treating the rapidly growing number of adults with obstructive sleep apnea (OSA), according to the company.
“After carefully considering the dental sleep medicine opportunity and MicroDental’s capabilities, the executive team agreed that a focused operation has the most potential to create value for dentists, their patients, employees, and shareholders,” says William Johnson, CEO of MicroDental, in a release.
At launch, Len Liptak, currently president of MicroDental Laboratories, will serve in a dual capacity as CEO of ProSomnus Sleep Technologies. Len is an experienced dental industry leader, with expertise operating and developing businesses driven by product innovation.
“ProSomnus invents and manufactures custom intraoral devices that enable dentists to treat obstructive sleep apnea with greater effectiveness, efficiency, and convenience,” says Liptak. “This strategy enables ProSomnus to accelerate key product development, process enhancement and patient education programs.”
Dave Kuhns, PhD, and Sung Kim are also slated to play a leadership role with ProSomnus. Kuhns and Kim each have invented and commercialized numerous orthodontic, dental restorative and prosthetic, and dental sleep medicine products. Kuhns joins ProSomnus as vice president of technology. Sung Kim joins ProSomnus as vice president of engineering.
“ProSomnus is the only company that precision manufactures intraoral devices, such as the MicrO2 Device, for the treatment of obstructive sleep apnea,” says Kim. “Our proprietary manufacturing platform allows ProSomnus to meet clinical requirements in terms of function, features, and also consistency, reliability, and service.”
“ProSomnus is focused on commercializing device designs that are clinically relevant, creating treatment experiences that exceed the needs of the practicing sleep dentist, and supporting scientific research that further establishes dental sleep medicine as a viable therapy for OSA,” says Kuhns.